Table 2

Clinical characteristics and fasting blood concentrations of several metabolic variables after 10 days of exenatide and placebo treatment in 36 patients completing crossover study 1

PlaceboExenatideChange*P value
Body weight (kg)101.4 ± 22100.7 ± 21.5−0.95 (−2 to 0.6)0.01
Systolic blood pressure (mmHg)131 ± 11126 ± 13−5.5 (−14 to 9)0.03
Diastolic blood pressure (mmHg)76 ± 976 ± 101 (−5 to 6.5)0.9
Heart rate (bpm)69 ± 1271 ± 111.5 (−5.5 to 5.5)0.2
Glucose (mg/dL)122 ± 25113 ± 23−7.5 (−17.5 to 3.5)0.01
Insulin (mU/L)12.3 (8.6–24)13.2 (8.8–25.6)0.8 (−1.5 to 4.4)0.2
Triglycerides (mg/dL)186 ± 104172 ± 77−16 (−51 to 34)0.4
Total cholesterol (mg/dL)163 ± 36150 ± 33−10 (−27 to 3)0.002
LDL cholesterol (mg/dL)80 ± 1081 ± 287 (−11 to 21)0.8
HDL cholesterol (mg/dL)38 ± 836 ± 7−1 (−6 to 2)0.048
  • Data are means ± SD or medians (25th–75th percentile). P values indicate comparison between the two treatment arms by repeated-measures ANCOVA adjusted for treatment sequence and diabetes duration group.

  • *Exenatide minus placebo.